Delivery Order SPE2DB20D9127-SPE2DB25FPRJ8
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml auto-injector on August 13, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was issued under the SPE2DB Indefinite Delivery Contract (IDC), a $500 million single-award vehicle that enables DLA to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. The...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 mg/mL syringes. The contract has a ceiling value of $3,094.80 and a period of performance through July 29, 2024. This contract was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which supports the recurring pharmaceutical supply...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $106,770.60 contract is for the delivery of XOLAIR 150 MG/ML SYRINGE to be completed by March 25, 2024. This delivery order is placed against DMS Pharmaceutical Group's larger indefinite delivery contract 4600082013 with DLA, valued at up to $4,999,999 through 2025, which enables DLA to order a broad range...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a...
- The U.S. Defense Logistics Agency (DLA) awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $8,561.10 for XOLAIR 150 mg/ml. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026. The award carries no set-aside designation...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 MG/ML syringes. The order has a potential value of $27,853.20 and a completion date of January 30, 2024. This order is placed against an existing indefinite delivery contract with DMS Pharmaceutical Group to provide a variety of pharmaceutical and medical supplies to support military treatment facilities globally. DMS Pharmaceutical...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRJ8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,547.40 to DMS Pharmaceutical Group Inc. for the supply of XOLAIR 150 mg/ml syringes. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, operates under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the prime contractor. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare systems. XOLAIR (omalizumab), a monoclonal antibody therapeutic, is a specialty pharmaceutical product typically used in the treatment of moderate-to-severe allergic asthma and other allergic conditions, representing the type of specialized pharmaceutical inventory the company maintains to support Defense Department medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/8/25 |